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DogBladder cancer is one of the leading lethal cancers worldwide. With the high risk of recurrence for bladder
cancer following the initial diagnoses, lifelong monitoring of patients is necessary. The lack of adequate
sensitivity and speciﬁcity of current noninvasive monitoring approaches including urine cytology, other
urine tests, and imaging, underlines the importance of studies that focus on the detection of more reliable
biomarkers for this cancer. The emerging area of metabolomics, which deals with the analysis of a large num-
ber of small molecules in a single step, promises immense potential for discovering metabolite markers for
screening and monitoring treatment response and recurrence in patients with bladder cancer. Since
naturally-occurring canine transitional cell carcinoma of the urinary bladder is very similar to human inva-
sive bladder cancer, spontaneous canine transitional cell carcinoma has been applied as a relevant animal
model of human invasive transitional cell carcinoma. In this study, we have focused on proﬁling the metab-
olites in urine from dogs with transitional cell carcinoma and healthy control dogs combining nuclear mag-
netic resonance spectroscopy and statistical analysis methods. 1H NMR-based metabolite proﬁling analysis
was shown to be an effective approach for differentiating samples from dogs with transitional cell carcinoma
and healthy controls based on a partial least square-discriminant analysis of the NMR spectra. In addition,
there were signiﬁcant differences in the levels of six individual metabolites between samples from dogs
with transitional cell carcinoma and the control group based on the Student's t-test. These metabolites
were selected to build a separate partial least square‐discriminant analysis model that was then used to
test the classiﬁcation accuracy. The result showed good classiﬁcation between transitional cell carcinoma
and control groups with the area under the receiver operating characteristic curve of 0.85. The sensitivity
and speciﬁcity of the model were 86% and 78%, respectively. These results suggest that urine metabolic
proﬁling may have potential for early detection of bladder cancer and of bladder cancer recurrence following
treatment, and may enhance our understanding of the mechanisms involved.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer (BC), and speciﬁcally transitional cell carcinoma
(TCC) was one of the leading lethal cancers worldwide. It was esti-
mated that 69,250 new cases of BC would be diagnosed and 14,990
deaths would result from this disease in the United States alone in
2011 [1]. The current standard approach to diagnose BC is cystoscopy
and histopathologic examination of the tissues collected atVeterinary Clinical Sciences,
.: +1 765 494 9900; fax: +1
etabolism Center, Department
h Lake Union, 850 Republican
), draftery@uw.edu
rights reserved.cystoscopy. Following diagnosis and treatment, there is a high risk of
BC recurrence. Patients with BC are monitored lifelong for recurrence
through urine cytology, other analyses performed on urine, imaging
and periodic cystoscopy [2–4]. However, none of the monitoring tech-
niques provide a non-invasive test with high sensitivity and speciﬁcity
for clinical use [5–7]. Recently, a few studies have focused on BC bio-
marker discovery, with the goal of ﬁnding reliable metabolites or pro-
teins that could make a signiﬁcant impact in the management of the
malignancy [4,8–11]. Urine contains tumor cells and metabolites shed
from the TCC mass in the bladder wall. BC biomarker discovery in
urinemay prove useful in detection of the cancer and in providing a bet-
ter understanding of how the cancer develops and progresses.
Metabolomics, also commonly known as metabolic proﬁling and
metabonomics, is a growing ﬁeld in systems biology [12,13], and
offers a powerful and promising approach to identify biomarkers as-
sociated with numerous cancers [14–17] and other diseases [18–24].
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nance (NMR) spectroscopy and mass spectrometry (MS) combined
with multivariate statistical analyses are the premier methods for
metabolomics-based studies [13,25]. While utilization of both NMR
and MS methods leads to the analysis of over 1000 small molecules
(molecular weight b1000 Da), various unsupervised and supervised
statistical methods create robust mathematical models to detect signif-
icant differences between cancer and healthy subjects arising from per-
turbations caused by disease processes, toxins, therapy or even diet
[26]. Key metabolites can be identiﬁed from the statistical results and
then validated as biomarker candidates [13]. However, there are few
BC metabolomic studies that have been reported to date [5,27]. Issaq
and co-workers analyzed human urine from BC patients and healthy
controls using liquid chromatography-mass spectrometry (LC-MS)
and stated the approach could be used as a potential noninvasive
early BC detection test [28]. Srivastava et al. observed a signiﬁcant ele-
vation in the concentration of taurine in urine of BC patients using
NMR, and proposed it as a possible biomarker for the non-muscle inva-
sive formof BC [29]. Two studies using gas chromatography–mass spec-
trometry (GC–MS), one based on global metabolomics and another
based on an amino acid targeted approach, have explored urinary me-
tabolites as diagnostic markers for human BC [30,31]. More recently,
the Huang group used two complementary LC separation techniques
to proﬁle human urinary metabolites and found carnitine C9:1 and an
unknown metabolite provided effective indication of BC using MS de-
tection [32]. However, to decrease themortality rate of BC, the develop-
ment ofmethods to detect the cancer earlier and to detect its recurrence
in a timely fashion, especially the exploitation of biomarkers that offer
high sensitivity and speciﬁcity, is still in great demand. In addition, in-
formation provided by metabolomics in the area of cancer biology
may be useful in further understanding the disease and how to prevent
and control it more effectively.
Naturally-occurring canine TCC of the urinary bladder has been
found to be very similar to human invasive BC not only in its histopath-
ologic characteristics and molecular features, but also in its biological
behavior including sites and frequency of metastasis, response to med-
ical therapy, and prognosis [33,34]. Spontaneous canine TCC has been
considered a highly relevant animal model of human invasive BC [35],
and it has been applied in studies of antitumor drug activity [36,37].
Several canine TCC cell lines have been established for mechanism
studies [38].
In this study, NMR combined with statistical analyses was used
to proﬁle and compare the urine metabolites from dogs with TCC
and healthy control dogs with no bladder disease, and the approach
was proven to be a powerful method for TCC biomarker discovery.
Six highly sensitive biomarker candidates, including urea, choline,
methylguanidine, citrate, acetone, and β‐hydroxybutyrate, were identi-
ﬁed. The power of these metabolites to distinguish the TCC and control
groups, in terms of their sensitivity, speciﬁcity, and level comparisons
were made. Factors such as different ages, genders and breeds were
also evaluated. Based on the identiﬁed biomarker candidates, intrinsic
disease-related mechanisms were discussed and suggested for further
studies. In particular, emerging methodologies in TCC metabolomics
in this studywere shown to be effective, and open a number of potential
avenues for further development and clinical applications.2. Materials and methods
2.1. Chemicals
Deuterium oxide (D2O, 99.9% D) was purchased from Cambridge
Isotope Laboratories, Inc. (Andover, MA). Trimethylsilylpropionic
acid-d4 sodium salt (TSP), sodium azide (NaN3), disodium hydrogen
phosphate (Na2HPO4), and monosodium phosphate (NaH2PO4) were
purchased from Sigma-Aldrich (analytical grade, St. Louis, MO).Deionized water was obtained from an EASYpure II UV water puriﬁca-
tion system (Barnstead International, Dubuque, IA).
2.2. Animal handling and urine collection
This work was approved by the Purdue Animal Care and Use
Committee. Dogs participating in the study were evaluated at the
Purdue University Veterinary Teaching Hospital. Participating dogs
included privately owned dogs with naturally-occurring invasive
TCC of the urinary bladder and/or urethra diagnosed by histopathol-
ogy, and privately owned healthy control dogs of similar age, breed,
and gender. In the dogs with TCC, thoracic radiography and abdom-
inal ultrasonography were used to help determine tumor stage. The
TNM stage was deﬁned following criteria established by the World
Health Organization (WHO) [39].
The control dogs had no evidence of TCC other cancer, any bladder
disease, major organ dysfunction, or illness. To help conﬁrm that the
control dogs did not have occult urinary tract disease, urine samples
were analyzed by dip stick exam (Multistix 10SG, Siemens, Washing-
ton, DC) and urine speciﬁc gravity. If any abnormalities were noted in
the urine of the control dogs, such as urinary tract infection or blood
in the urine, the dogs were excluded from the study.
Midstream free catch urine samples (10 mL) were collected from
the dogs. Sodiumazide (0.1%)was added to the samples. The urine sam-
ples were centrifuged, and the supernatants stored at −80 °C until
metabolomic analyses were performed.
2.3. NMR spectroscopy
The experimental methods used for NMR analysis have been pub-
lished elsewhere [18]. Brieﬂy, frozen urine samples were thawed, and
300 μL was mixed with 300 μL phosphate buffer (pH 7.4, 0.5 M). Each
resulting solution was centrifuged at 13,200 rpm for 10 min to remove
particulate matter, if any was present. 550 μL of the supernatants were
transferred to 5-mm NMR tubes. A 50 μL of TSP (0.06 mg/mL in D2O)
was also transferred into each tube, and utilized as the chemical shift
reference (δ=0.00). All 1H NMR experiments were carried out at
25 °C on a Bruker DRX-500 spectrometer equipped with a cryogenic
probe and triple axismagnetic ﬁeld gradients. 1H NMR spectra were ac-
quired using the standard one-dimensional NOESY pulse sequencewith
water presaturation. Each dataset was averaged over 64 transients
using 16 K time domain points and 7 kHz spectral width. The data
were Fourier transformed after multiplying by an exponential window
function corresponding to a line broadening of 1 Hz. The spectra were
then phase and baseline corrected using Bruker TopSpin software (ver-
sion 3.0).
2.4. Data analysis
NMR spectral were binned to 4 K buckets of equal width
(0.0034 ppm) to minimize errors due to any ﬂuctuations of chemical
shifts arising from pH or ion concentration variations. Each spectrum
was aligned to themethyl peak of alanine at 1.48 ppm, andwas normal-
ized using the integrated creatinine signal at 4.05 ppm. Spectral regions
within the range of 0.3 to 10.0 ppmwere used for the analysis after de-
leting the region containing water residual signals (4.5 to 5.0 ppm).
Univariate analysis was performed by applying the unpaired Student's
t-test to identify signiﬁcantly different spectral bins among samples
from dogs with TCC and healthy controls. The characteristic spectral
regions for each metabolite were then integrated, and p-values and
fold changes between different groups were calculated.
To classify cancer and control groups, statistical analysis was
performed on the whole (binned) spectral data using partial least
square discriminant analysis after orthogonal signal correction
(OSC-PLS-DA). For this analysis, the binned NMR data were imported
into Matlab (R2008a, Mathworks, MA) installed with a PLS toolbox
Table 1
Summary of clinicopathogical characteristics of dogs with invasive transitional cell car-
cinoma (TCC) and controls.
Characteristics TCC dogs Control dogs
Number 40 42
Chronological age (yrs, mean±SD) 9.8±2.1 6.7±2.8
Standardized age in
human equivalentsa (yrs, mean±SD)
55.5±7.6 42.7±11.8
≤45 yrs 3 21
>45 yrs 37 21
Gender (male/female) 30/10 17/25
Breed
Scottish Terrier 9 8
Shetland Sheepdog 8 6
West Highland
White Terrier
1 1
Others 22 27
Cancer stage and gradeb
T0 2
T2 29
T3 9
N0 37
N1 3
M0 31
M1 9
Nodal or distant metastasis
developed before death
Yes 26
No 10
Unknown 4
a Converted from chronological age according to Reference [41].
b Stage deﬁned by World Health Organization criteria for canine bladder tumors
[39].
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OSC corrected NMR spectral variables; the Y matrix consisted of “0”
and “1” for TCC and control samples, respectively. We then
performed PLS-DA using peak integrals of the selected metabolites
as X matrix inputs. Subsequently, the performance of the PLS-DA
models was assessed by Monte Carlo Cross Validation (MCCV) anal-
ysis [40] using 100 iterations as well as another 100 iterations for
permutation analysis. For MCCV analysis, all samples were randomly
divided into two sets, 60% of the samples were used as the training
set and 40% as the test set with and without (for permutation analy-
sis) true class assignment. For each iteration, the training set was
5-fold cross-validated and used to predict the class membership of
the test set samples. Selected metabolites with pb0.05 were also
analyzed using the same approach. Predictions were made visually
using a Y-predicted scatter plot with a cut-off value chosen forFig. 1. Typical 500 MHz 1H NMR spectra of urine obtained from (A) a dog with transitional ce
alanine; 4, acetate; 5, acetone; 6, pyruvate; 7, citrate; 8, dimethylamine; 9, methylguanidine; 10,
allantoate; 17, urea; 18, cis-aconitate; 19, (phenylacetyl)glycine; 20, formate; 21, N-methylnicotinpotential class membership. The R statistical package (version
2.8.0) was used to generate box-and-whisker plots and receiver op-
erating characteristics (ROC) curves, calculate and compare the sen-
sitivity, speciﬁcity and the area under the ROC curve (AUROC).
3. Results and discussion
3.1. Biomarker discovery and evaluation
Clinical data were obtained from 40 dogs with TCC and 42 con-
trols. The clinicopathological characteristics are summarized in
Table 1. To minimize the effect of breed and body size on dog age,
each dog's age was converted to human year equivalents as previous-
ly described [41].
Representative 1H NMR spectra of samples from the TCC group
and the control group are shown in Fig. 1, along with the metabolite
assignments. As listed in Table S1, a total of 21 metabolites were
assigned to the corresponding resonances by comparing chemical
shifts and multiplicities of peaks to the previously reported data
[42,43]. In order to remove the inﬂuences attributed to muscle mass
and urine concentration [43,44], the NMR data were normalized to
the integrated creatinine resonance at 4.05 ppm. The normalized
NMR whole spectral data were further analyzed by orthogonal signal
correction pretreated PLS-DA (OSC-PLS-DA) to differentiate the urine
of dogs with TCC from healthy controls. The OSC-PLS-DA score plot
shows a clear separation, indicating a metabolic difference between
the two dog groups (Fig. 2A). In the ﬁgure, TCC dogs are represented
by an open square and healthy controls are represented by a solid cir-
cle. Monte Carlo Cross Validation (MCCV) was then applied to further
evaluate the classiﬁcation ability of the whole NMR spectra. The pre-
dictions for the true class assigned models and permuted models
were plotted in an ROC space as shown in Fig. 2B. The permuted
model results, which clustered at the center of the ROC, indicate no
discrimination. And the true class assigned models all showed high
sensitivity and speciﬁcity, which gave evidence for the good classiﬁ-
cation ability of the PLS-DA model. Analysis of the loading plots indi-
cates that a number of metabolites including all of those shown in
supplementary Table S1 (except taurine), along with bile acids, thre-
onine, dimethylamine and betaine contribute to the discrimination.
We decided to also pursue a more targeted metabolomics approach
in this study to focus on individual metabolites with individual statisti-
cal signiﬁcance. A major drawback of multivariate model building such
as OSC-PLS-DA using the full data as shown in Fig. 2 is that suchmodels
typically rely on the contributions from numerous small peaks, many of
which are currently unknown metabolites, or even chemical noise. Inll carcinoma (TCC) and (B) a healthy control dog. Key: 1, β-hydroxybutyrate; 2, lactate; 3,
creatine; 11, choline; 12, trimethylamine N-oxide; 13, taurine; 14, creatinine; 15, glucose; 16,
amide.
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Fig. 2. (A) OSC-PLS-DA score plot, and (B) Monte Carlo Cross Validation (MCCV) prediction results of the PLS-DA model plotted as sensitivity vs 1-speciﬁcity based on the 1H NMR
spectra of samples from 42 control dogs and 40 dogs with TCC.
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perfect spectral baselines, peak misalignments, and strong uneven sol-
vent backgrounds. The positions of NMR signals speciﬁcally in urine
are often sensitive to subtle differences in parameters such as pH,
ionic strength, temperature or concentration of macromolecules. Peak
shifts combined with baseline distortions can translate into spectral
bins that do not represent true peak intensity and pose a signiﬁcant
challenge to the accuracy of the outcome. The problem becomes more
severe when the metabolite peaks involved are of low intensity.
The quantitative metabolomics approach that we have pursued here
alleviates these issues by correctly identifying peak regions, followed
by application of local base line corrections wherever needed, and
then peak integration.
As a result of this process, individual peaks from 21 known
metabolites (Supplementary Table S1) were integrated, and their
p-values between the TCC and control groups were calculated. Six
metabolites, urea, choline, methylguanidine, citrate, acetone and
β‐hydroxybutyrate, were signiﬁcantly different between dogs with
TCC and control dogs (pb0.05). These 6 metabolites were consid-
ered as biomarker candidates in the following analysis and discus-
sion, and their relative concentrations in both the TCC and control
groups, p-values and fold changes are shown in Table 2. Also, the
ranges of each metabolite concentration for the TCC and control
samples are shown as box-and-whisker plots in Fig. 3. Both the
results from Table 2 and Fig. 3 indicate that all the median levels of
the 6 marker candidates increased from controls to dogs with TCC.
PLS-DA was then utilized to build a multivariate model to evaluate the
potential biomarker candidates. The 6 metabolites were selected asTable 2
Metabolites that are signiﬁcantly different between dogs with transitional cell carcino-
ma (TCC) and controls.
Metabolite Relative concentrationa
(mean±SD)
p-Value FCb (TCC/
control)
Control TCC
Urea 1452.8±615.4 2000.0±970.0 3.04E−03 1.37
Choline 65.9±31.2 109.7±99.2 9.86E−03 1.63
Methylguanidine 31.4±7.9 37.3±16.1 3.44E−02 1.19
Citrate 325.6±281.9 857.8±801.8 7.71E−04 2.56
Acetone 44.1±15.3 55.2±26.8 2.92E−02 1.24
β-hydroxybutyrate 72.6±25.5 119.5±50.1 1.51E−06 1.62
a μM/mM of creatinine.
b Fold change.the variables to build this second PLS-DA model. Leave-one-out cross-
validation was performed to obtain the best model and avoid over-
ﬁtting. Six LVs were used based on the RMSECV (Root-Mean-Square
Error of Cross-Validation) procedure usingMatlab, and the cross valida-
tion error was estimated as 20.9%. The need for 6 LVs is likely due to the
fact that most of the metabolite correlations are modest and mostly
decrease in TCC compared to normal (Fig. S2). The prediction plot of
the group membership from the PLS-DA model is shown as in Fig. 4A,
in which most samples were well classiﬁed using a cut-off of 0.0034.
In Fig. 4B, ROC curve analysis using the cross-validated predicted Y (pre-
dicted class) values was utilized to judge the sensitivity and speciﬁcity
of the PLS-DAmodel. The AUROCwas 0.85, and the sensitivity and spec-
iﬁcity for TCC detection were 86% and 78%, respectively. In a similar
validation process as described above for the whole spectral data,
MCCV was applied to the group of 6 marker candidates, and the results
shown in Fig. 4C validate the good sensitivity and speciﬁcity of the true
class assigned models and the non-discriminating permuted models.
3.2. Effect of gender, age, breed and TNM stage
Previous reports have shown that a series of factors, including
gender, age, breed, and TNM stage, may result in distinctive canine
metabolic differences [33,43,45]. Therefore, to further evaluate the
marker candidates, p-values for the 6 metabolites comparing age,
gender and breed between dogs with TCC and controls were calculated
and shown in Table 3A, B and C, respectively. The p-values of themarker
candidates between ages, genders and breeds within the control and
TCC groupswere also calculated as shown in Table S2. In terms of differ-
ent ages, genders and breeds, the 6 metabolites in TCC group rarely
showed much difference.
Typically, canine TCC is a disease found in older dogs. In this study,
dogs with a standardized age of 45 and higher were considered as
the old group and the rest as the young group. Within the control
dogs, the number of old and young subjects was both 21, and the
p-values of all 6marker candidates between old and young dogs indicat-
ed no signiﬁcant difference as listed in Table S2. However, as shown in
Table 3A, urea, choline, citrate and β–hydroxybutyrate showed signiﬁ-
cant differences (pb0.05) between TCC and control dogs within the
old group, while no metabolite had a low p-value in the young group
(although this may partly be due to the small TCC sample number).
These data indicate that the markers are not age-dependent, and urea,
choline, critate and β‐hydroxybutyrate could be used to distinguish
dogs with TCC from controls, at least for the older dogs.
Unlike humans, female dogs are conﬁrmed to have an increased
risk of developing BC [34]. All marker candidates showed p>0.05
Fig. 3. Box-and-whisker plots of the candidate metabolite markers. The y-axis represents the relative concentration level of each metabolite normalized by the concentration of
creatinine (μM/mM). Horizontal line in the middle portion of the box, median; bottom and top boundaries of boxes, lower and upper quartile; wiskers, 5th and 95th percentiles;
open circles, outliers.
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gender-dependent (Table S2). However, as shown in Table 3B, all
6 marker candidates are more sensitive to the male dogs, and only
β‐hydroxybutyrate is useful in distinguishing TCC from control in
female dogs.A 
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tabolite markers, and (B) receiver operating characteristics (ROC) curve using the
sensitivity and speciﬁcity were 86% and 78%, respectively. (C) Monte Carlo Cross Val-
Table 3
Student's t-test results for comparisons among various groups.
Metabolite p-Value (TCC vs control)
(A) Age (B) Gender (C) Breed
≤45
yrsa
>45
yrsa
Female Male At-risk
breedsb
Other
breeds
Urea 0.22 6.5E−04 0.12 0.013 0.18 0.0048
Choline 0.84 0.021 0.14 0.024 0.30 0.024
Methylguanidine 0.35 0.19 0.34 0.021 0.13 0.22
Citrate 0.47 0.0013 0.23 0.00069 0.26 0.0010
Acetone 0.26 0.14 0.16 0.020 0.25 0.056
β-hydroxybutyrate 0.26 2.4E−05 0.0054 2.5E−05 0.011 0.00017
a Standardized age.
b At-risk breeds including Scottish Terrier, Shetland Sheepdog and West Highland
White Terrier.
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breeds. Herein, these three breeds were grouped as at-risk breeds, in
which β‐hydroxybutyrate was associated with a small p-value in
comparing the TCC dogs and controls. For the other breeds, the
p-values of urea, choline, citrate and β‐hydroxybutyrate were
all below 0.05 (Table 3C and Fig. S3). Interestingly, even within
the control dogs, the levels of methylguanidine, citrate, acetone
and β‐hydroxybutyrate were signiﬁcantly different (Table S2).
The results showed that the marker levels in the at-risk breed
group (either controls or TCC dogs) are larger than their counter-
parts in non-risk controls and comparable to their counterparts in
non-risk TCC dogs. Therefore, the p-values of at-risk control vs
at-risk TCC are large; however, in the other breeds, the p-values are
small. This result may suggest why Scottish Terriers, West Highland
White Terriers and Shetland Sheepdogs are at-risk breeds for TCC at
the molecular level: the at-risk dogs may have different metabolism,
which contributes to their susceptibility to developing TCC.
In addition, lymphatic spread and distant spread effects were also
investigated among the samples from dogs with TCC. Large p-values
were observed between T0/T2 vs T3; N1 or M1 vs others; cases that
never developed metastases vs those that did develop metastases
along the course of their disease; and distant metastases vs no distant
metastases for each of the six markers, which indicates that none of
these factors is signiﬁcant in the classiﬁcation (data not shown).
3.3. Metabolic pathway analysis
Altered pathways in canine TCCwere identiﬁed based on themetab-
olites that showed signiﬁcant level changes in samples from dogs with
TCC versus control samples. A simpliﬁed pathway map is shown inFig. 5. Simpliﬁed altered metabolism pathways for the most relevant metabolic differences
were biomarkers observed as being upregulated in dogs with TCC.Fig. 5 based on the KEGG online database (http://www.genome.jp/
kegg/pathway.html).
Increased amounts of β-hydroxybutyrate, acetone and citrate
indicate upregulation of the synthesis of ketone bodies and activity
of the TCA cycle in the tumor cells. These elevated levels were also
found in human serum of esophageal cancer patients and plasma of
mice with prostate tumors [17,46]. The Cori cycle might fail to convert
lactate back to glucose in the liver when the lactate is abundant,
which results in the accumulation of Acetyl-CoA and citrate
up-regulation in the TCA cycle sequentially [47]. If the Acetyl-CoA is
not well accommodated by the TCA cycle, ketogenesis will take place
and ketone bodies, including acetone and β-hydroxybutyrate, will be
converted [46], thus, levels of acetone andβ-hydroxybutyratewould in-
crease in dogs with TCC compared with healthy controls.
As an important precursor of cell membrane constitution, choline
was also found to be present at higher levels in the TCC specimens.
Similar observations have been reported in a number of other
NMR-based disease studies such as studies of human colorectal
cancer [48,49], cerebral gliomas [50], cervical cancer [51], and bipo-
lar disorder [52]. One possible reason for the choline upregulation
could be membrane turnover [50]; while another key factor could
be the increased glycerophospholipid metabolism due to the lactate
accumulation discussed above.
Moreover, elevations of urea and methylguanidine levels were
observed in the urine of dogs with TCC. Methylguanidine is synthe-
sized from creatinine concomitant with the synthesis of hydrogen
peroxide from endogenous substrates in peroxisomes, and is consid-
ered as a uremic toxin accumulated in uremic patients [53]. As the
principal end product of protein catabolism, urea is formed in the
urea cycle, where amino groups donated by ammonia and L-aspartate
are converted to urea.4. Conclusions
A metabolomics approach based on 1H NMR coupled with the
statistical methods of OSC-PLS-DA and univariate Student's t-test
based feature (metabolite) selection provides a powerful method-
ology for metabolic proﬁling of urine to differentiate dogs with TCC
from healthy controls. Six candidate metabolite markers, including
urea, choline, methylguanidine, citrate, acetone and β‐hydroxybutyrate
were found to have good discriminatory ability and low p-values. Good
sensitivity and selectivitywas shown using thesemarkers to predict the
healthy control and disease samples,which indicates thepromise of this
approach towards the development of a metabolic proﬁle for TCC and
potentially its earlier detection. Further analysis involving a largerbetween dogs with TCC and controls. The metabolites highlighted with rounded boxes
1813J. Zhang et al. / Biochimica et Biophysica Acta 1822 (2012) 1807–1814number of subjects is required to determine the accuracy andwidespread
applicability of this and similar approaches in guiding treatment of TCC.
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